Form 4: VolitionRx CCO Forterre Reports RSU Tax Withholding

VolitionRx's Chief Commercial Officer, Gael Forterre, reported the disposition of 5,251 common shares for tax withholding related to restricted stock unit settlement.

Summary

• Gael Forterre, Chief Commercial Officer of VolitionRx Ltd (VNRX), reported a transaction on March 17, 2026.
• The transaction involved the disposition of 5,251 shares of common stock at a price of $0.19 per share.
• These shares were retained by VolitionRx for cancellation to satisfy tax withholding obligations upon the settlement of 12,700 restricted stock units (RSUs).
• No shares were sold by Mr. Forterre or VolitionRx in this transaction.
• Following the transaction, Mr. Forterre directly beneficially owns 331,338 shares of common stock.
• Additionally, 5,000 shares are indirectly owned by his spouse, and 32,500 shares are indirectly owned by Armorica Partners, LLC, where Mr. Forterre is the managing director and sole shareholder.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting the routine vesting of executive equity compensation and the standard tax withholding process, with no direct positive or negative implications for company operations or strategy.

Positives

• The settlement of 12,700 restricted stock units indicates the vesting of previously granted equity compensation for the Chief Commercial Officer, reflecting continued executive alignment with shareholder interests.

Negatives

• The disposition of 5,251 shares for tax withholding reduces the direct beneficial ownership of the Chief Commercial Officer, though this is a standard procedure for RSU vesting.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider filings like Form 4, detailing equity compensation vesting and associated tax withholdings, are common across all industries for publicly traded companies. This specific transaction reflects standard compensation practices for executive officers.

Related Party Transactions

• Gael Forterre indirectly beneficially owns 32,500 shares through Armorica Partners, LLC, where he is the managing director and sole shareholder, exercising voting and dispositive control. He disclaims beneficial ownership except for his pecuniary interest.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event. It slightly reduces the direct holdings of a key executive but reflects the vesting of previously granted equity.
• Employees: Reflects standard executive compensation practices, which may be viewed as a positive for executive retention.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and subsequent tax withholding. Such events are standard executive compensation practices and typically do not indicate any material change in the company's fundamentals or future prospects. Therefore, it does not provide a basis for altering an existing investment thesis, leading to a 'hold' recommendation.

Keywords

VolitionRx, VNRX, Gael Forterre, Chief Commercial Officer, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSU, Tax Withholding, Equity Compensation